๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Prednisone

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 78 trials in our China, USA, UK, Ireland and India registers that name Prednisone as an intervention. Synced 24 Sep 2026
78Trials tracked
33Recruiting now
42Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Prednisone is named as a drug or biological intervention in 78 clinical trials in our China, USA, UK, Ireland and India trial registers, 33 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (6), Janssen Research & Development, LLC (6) and Hoffmann-La Roche (4). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1, Phase 2/3, Phase 4, Not applicable and Observational. Conditions studied include Prostate Cancer; Prostatic Neoplasms; Diffuse Large B-Cell Lymphoma.

Prednisone also has an approved-drug profile on this site (FDA label data): Deltasone (Prednisone) →
01

Clinical trials of Prednisone

78 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06090890 Anti-inflammatory Therapy for Recurrent In-stent Restenosis (ClinicalTrials.gov ↗)
In-stent Restenosis
 Phase 4 Recruiting Fu Wai Hospital, Beijing, China China
NCT06498089 A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis (ClinicalTrials.gov ↗)
Takayasu Arteritis
 Phase 4 Recruiting Shanghai Zhongshan Hospital China
NCT07719140 Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial) (ClinicalTrials.gov ↗)
Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
 Phase 4 Recruiting Peking Union Medical College Hospital China
NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (ClinicalTrials.gov ↗)
Lymphoblastic Lymphoma, Childhood
 Phase 3 Recruiting University Hospital Muenster Ireland, China
NCT06136624 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (ClinicalTrials.gov ↗)
Prostate Cancer Metastatic
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06533098 A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (ClinicalTrials.gov ↗)
Thrombocytopenia, Neonatal Alloimmune
 Phase 3 Recruiting Janssen Research & Development, LLC UK, USA
NCT06624670 A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (ClinicalTrials.gov ↗)
Pyoderma Gangrenosum
 Phase 3 Recruiting LEO Pharma USA, China
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06925737 A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (ClinicalTrials.gov ↗)
Prostate Cancer, Prostatic Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT07168161 BDB-001 Phase III Trial in ANCA-Associated Vasculitis (ClinicalTrials.gov ↗)
ANCA Associated Vasculitis (AAV)
 Phase 3 Recruiting Staidson (Beijing) Biopharmaceuticals Co., Ltd China
NCT03804931 Fecal Microbiota Transplantation for Ulcerative Colitis (ClinicalTrials.gov ↗)
Ulcerative Colitis, Fecal Microbiota Transplantation
 Phase 2/3 Recruiting Guangzhou First People's Hospital China
NCT06563245 Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (ClinicalTrials.gov ↗)
Classical Hodgkin Lymphoma, Child, Adolescent
 Phase 2/3 Recruiting Children's Cancer Group, China China
NCT07068165 A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease (ClinicalTrials.gov ↗)
IgG4 Related Disease
 Phase 2/3 Recruiting Peking Union Medical College Hospital China
NCT07412470 A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Kidney Transplant Rejection
 Phase 2/3 Recruiting Sanofi UK, USA, China
NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Follicular Lymphoma
 Phase 2/3 Recruiting Merck Sharp & Dohme LLC USA, China
NCT04440267 Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage (ClinicalTrials.gov ↗)
Acute Leukemia of Ambiguous Lineage
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT05039619 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
 Phase 2 Recruiting Hoffmann-La Roche UK, USA
NCT05958719 Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Peripheral T Cell Lymphoma, Epigenetic Repression
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT06700798 Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL๏ผš A Randomized, Open Phase II Trial (ClinicalTrials.gov ↗)
Marginal Zone Lymphoma(MZL)
 Phase 2 Recruiting Fei Li China
NCT06704555 Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06803693 Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT06890884 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (ClinicalTrials.gov ↗)
Lymphoma, Large B-Cell, Diffuse
 Phase 2 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT07005154 A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (ClinicalTrials.gov ↗)
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
 Phase 2 Recruiting Astellas Pharma Global Development, Inc. UK, USA, China
NCT04300556 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRฮฑ)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (ClinicalTrials.gov ↗)
Solid Tumor
 Phase 1/2 Recruiting Eisai Inc. UK, USA
NCT04432714 Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement (ClinicalTrials.gov ↗)
DLBCL, Untreated, MYC Gene Rearrangement
 Phase 1/2 Recruiting The First Affiliated Hospital with Nanjing Medical University China
NCT06353386 Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (ClinicalTrials.gov ↗)
Prostatic Neoplasms, Castration-Resistant
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06564038 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
 Phase 1/2 Recruiting AstraZeneca UK, USA, China
NCT07124936 A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B Cell Lymphoma (DLBCL)
 Phase 1/2 Recruiting Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. China
NCT04729114 A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (ClinicalTrials.gov ↗)
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
 Phase 1 Recruiting Astellas Pharma Global Development, Inc. USA
NCT05176483 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (ClinicalTrials.gov ↗)
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)
 Phase 1 Recruiting Exelixis UK, USA
NCT07339267 A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer (ClinicalTrials.gov ↗)
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
 Phase 1 Recruiting Astellas Pharma Global Development, Inc. China
NCT04918524 The Clinical Features and Pregnancy Outcomes of CTD Patients (ClinicalTrials.gov ↗)
Connective Tissue Diseases, Pregnancy Related
 Observational Recruiting Qilu Hospital of Shandong University China
NCT07431060 Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (ClinicalTrials.gov ↗)
Langerhans Cell Histiocytosis (LCH)
 Not applicable Recruiting West China Second University Hospital China
NCT07451665 Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (ClinicalTrials.gov ↗)
Takayasu Arteritis (TAK)
 Phase 4 Not yet open Chinese SLE Treatment And Research Group China
NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma ( FL)
 Phase 3 Not yet open Ruijin Hospital China
NCT07712588 Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 2/3 Not yet open Dizal Pharmaceuticals China
NCT06614985 The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy (ClinicalTrials.gov ↗)
Primary Membranous Nephropathy
 Phase 2 Not yet open Renmin Hospital of Wuhan University China
NCT07231250 Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody
 Phase 2 Not yet open Li Zhiming China
NCT07535762 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (ClinicalTrials.gov ↗)
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
 Phase 2 Not yet open Shanghai Jiao Tong University School of Medicine China
NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL (ClinicalTrials.gov ↗)
Large B-Cell Lymphoma (LBCL)
 Phase 2 Not yet open Ruijin Hospital China
NCT07746245 The Efficacy of CAPCT in Patients With PTCL (ClinicalTrials.gov ↗)
Peripheral T-Cell Lymphoma
 Phase 2 Not yet open The First Affiliated Hospital with Nanjing Medical University China
NCT07535710 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma (ClinicalTrials.gov ↗)
Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome
 Phase 1/2 Not yet open Shanghai Jiao Tong University School of Medicine China
NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 1/2 Not yet open Ruijin Hospital China
NCT06789315 Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis (ClinicalTrials.gov ↗)
Alcoholic Hepatitis
 Not applicable Not yet open Institute of Liver and Biliary Sciences, India India
NCT05678933 AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH (ClinicalTrials.gov ↗)
Peripheral T-cell Lymphoma Targeted Therapy
 Phase 3 By invitation Tianjin Medical University Cancer Institute and Hospital China
NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (ClinicalTrials.gov ↗)
Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)
 Phase 3 By invitation Exelixis USA
NCT06468943 Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (ClinicalTrials.gov ↗)
Effects of Chemotherapy, Safety Issues
 Phase 2 By invitation The First Affiliated Hospital of Soochow University China
NCT04833907 rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (ClinicalTrials.gov ↗)
Canavan Disease
 Phase 1/2 By invitation Myrtelle Inc. USA
NCT05457257 Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (ClinicalTrials.gov ↗)
Metastatic Castration-resistant Prostate Cancer
 Phase 4 Active, closed AstraZeneca China
NCT02257736 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (ClinicalTrials.gov ↗)
Prostatic Neoplasms
 Phase 3 Active, closed Aragon Pharmaceuticals, Inc. UK, USA
NCT03589326 A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia (ClinicalTrials.gov ↗)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
 Phase 3 Active, closed Takeda USA, China
NCT03748641 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (ClinicalTrials.gov ↗)
Castration-Resistant Prostatic Cancer
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT04221477 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis (ClinicalTrials.gov ↗)
Lupus Nephritis
 Phase 3 Active, closed Hoffmann-La Roche UK, USA
NCT04446117 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (ClinicalTrials.gov ↗)
Metastatic Prostate Cancer, Prostate Adenocarcinoma
 Phase 3 Active, closed Exelixis UK, USA
NCT04497844 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) (ClinicalTrials.gov ↗)
Prostatic Neoplasms
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Acerta Pharma BV USA, India, China
NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (ClinicalTrials.gov ↗)
Diffuse Large B-cell Lymphoma
 Phase 3 Active, closed Incyte Corporation Ireland, UK, USA
NCT05288166 A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (ClinicalTrials.gov ↗)
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms
 Phase 3 Active, closed Eli Lilly and Company UK, USA, China
NCT05578976 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Genmab UK, USA, China
NCT05605899 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗)
High-risk Large B-cell Lymphoma (LBCL)
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT06047080 An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Large B-Cell Lymphoma
 Phase 3 Active, closed Hoffmann-La Roche UK, USA, China
NCT06143891 A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ClinicalTrials.gov ↗)
Chronic Graft Versus Host Disease
 Phase 3 Active, closed Sanofi UK, USA, China
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Active, closed Genmab UK, USA, China
NCT06356129 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 3 Active, closed Celgene USA, India, China
NCT03706365 A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Prostate Cancer
 Phase 2/3 Active, closed Eli Lilly and Company USA, China
NCT02960022 A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (ClinicalTrials.gov ↗)
Prostate Cancer
 Phase 2 Active, closed Astellas Pharma Global Development, Inc. UK, USA, China
NCT03431350 A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (ClinicalTrials.gov ↗)
Prostatic Neoplasms, Castration-Resistant
 Phase 2 Active, closed Janssen Research & Development, LLC UK, USA
NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Active, closed Hoffmann-La Roche USA
NCT05283720 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗)
Non-Hodgkin Lymphoma
 Phase 2 Active, closed Genmab USA, China
NCT05673785 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Active, closed Takeda China
NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, Follicular
 Phase 2 Active, closed Celgene UK, USA
NCT03920007 Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Leber Congenital Amaurosis, LCA, LCA1
 Phase 1/2 Active, closed Atsena Therapeutics Inc. USA
NCT04411654 Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) (ClinicalTrials.gov ↗)
Gaucher Disease, Type 2
 Phase 1/2 Active, closed Prevail Therapeutics UK, USA
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗)
B-Cell Non-Hodgkin Lymphoma
 Phase 1/2 Active, closed Genmab China
NCT02123758 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
 Phase 1 Active, closed Aragon Pharmaceuticals, Inc. UK, USA
NCT04577833 A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Prostatic Neoplasms
 Phase 1 Active, closed Janssen Research & Development, LLC UK, USA
NCT04662580 ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (ClinicalTrials.gov ↗)
Metastatic Prostate Cancer
 Phase 1 Active, closed Janssen Research & Development, LLC USA
NCT04884035 Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, B-Cell
 Phase 1 Active, closed Celgene USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

93 conditions
Condition (as registered)Trials
Prostate Cancer6
Prostatic Neoplasms6
Diffuse Large B-Cell Lymphoma4
Large B-cell Lymphoma3
Metastatic Castration-Resistant Prostate Cancer3
Prostatic Neoplasms, Castration-Resistant2
Lupus Nephritis2
Solid Tumor2
Renal Cell Carcinoma (RCC)2
Metastatic Hormone Sensitive Prostate Cancer2
Metastatic Prostate Cancer2
Follicular Lymphoma2
Lymphoma2
Prostate Cancer Metastatic1
Lymphoblastic Lymphoma, Childhood1
Diffuse Large B-cell Lymphoma1
Lymphoma, Large B-Cell, Diffuse1
Chronic Lymphocytic Leukaemia1
Small Lymphocytic Lymphoma1
Mantle-cell Lymphoma1
Follicular Lymphoma (FL)1
Thrombocytopenia, Neonatal Alloimmune1
Castration-Resistant Prostatic Cancer1
Neoplasm Metastasis1
Urogenital Neoplasms1
Physiological Effects of Drugs1
Kidney Transplant Rejection1
High-risk Large B-cell Lymphoma (LBCL)1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)1
Urothelial Carcinoma (UC)1
Lymphoma, Follicular1
Prostate Adenocarcinoma1
Large B-Cell Lymphoma1
Gaucher Disease, Type 21
Chronic Graft Versus Host Disease1
Leber Congenital Amaurosis1
LCA1
LCA11
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)1
Lymphoma, B-Cell1

+ 53 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Merck Sharp & Dohme LLC6
Janssen Research & Development, LLC6
Hoffmann-La Roche4
Genmab4
Astellas Pharma Global Development, Inc.4
Ruijin Hospital4
Exelixis3
Celgene3
AstraZeneca2
Aragon Pharmaceuticals, Inc.2
Eli Lilly and Company2
Sanofi2
Takeda2
Institute of Hematology & Blood Diseases Hospital, China2
Tianjin Medical University Cancer Institute and Hospital2
The First Affiliated Hospital with Nanjing Medical University2
Peking Union Medical College Hospital2
Shanghai Jiao Tong University School of Medicine2
University Hospital Muenster1
Incyte Corporation1
Eisai Inc.1
Kite, A Gilead Company1
Prevail Therapeutics1
Atsena Therapeutics Inc.1
LEO Pharma1
Acerta Pharma BV1
Myrtelle Inc.1
Institute of Liver and Biliary Sciences, India1
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1
Fu Wai Hospital, Beijing, China1
Staidson (Beijing) Biopharmaceuticals Co., Ltd1
West China Second University Hospital1
Li Zhiming1
Chinese SLE Treatment And Research Group1
Children's Cancer Group, China1
Qilu Hospital of Shandong University1
Dizal Pharmaceuticals1
Shanghai Zhongshan Hospital1
The First Affiliated Hospital of Soochow University1
Guangzhou First People's Hospital1
Fei Li1
Renmin Hospital of Wuhan University1
04

Trials by country register

RegisterPrednisone trials
Clinical trials in China55
Clinical trials in USA44
Clinical trials in UK29
Clinical trials in Ireland6
Clinical trials in India3

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Prednisone works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prednisone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.